Singapore, April 11, 2023 – Update on Detection of the latest SARS-CoV-2 Variant
Credo Diagnostics Biomedical Pte Ltd continues the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using BLASTn analysis comparing primers and probes of the assays involving SARS-CoV-2 virus detection to the sequences listed in GISAID from January 1st, 2023 to March 31st, 2023.
We are pleased to announce that our VitaPCR™ system is capable of detecting the Omicron XBB.1.9.1 and XBB.1.16 subvariants and our analysis has confirmed that the performance of our SARS-CoV-2 RNA detection assays* is not impacted by the Omicron subvariant, XBB.1.9.1 and XBB.1.16.
*The SARS-CoV-2 RNA detection assays include:
. VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
. VitaPCR™ SARS-CoV-2 Assay (PCRAE0114)
. VitaPCR™ SARS-CoV-2 Gen 2 Assay (PCRAE0120)
For more information, contact us at service@credodxbiomed.com.